AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02143076 — intervention group
Intervention type: BEHAVIORAL
Intervention: Demographic Questionnaire
Description: At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
Study NCT02143076 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medical Adherence Measure Questionnaire
Description: At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment.
Study NCT02143076 — intervention group
Intervention type: BEHAVIORAL
Intervention: Acceptability Questionnaire
Description: At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment.
Study NCT03325946 — intervention group
Intervention type: BEHAVIORAL
Intervention: ACQUIRE Therapy
Description: Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
Study NCT02307682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab ophthalmic solution
Description: Ophthalmic solution for IVT injection
Study NCT02307682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept ophthalmic solution
Description: Ophthalmic solution for IVT injection
Study NCT04214067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04214067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04214067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04214067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03301870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 Gel 4%
Description: 4% active gel
Study NCT03301870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-rays
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-rays
Study NCT01553214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: Donors shall receive G-CSF 480 mcg as a single 1.6-mL subcutaneous injection 12 to 24 hours prior to donation.
Study NCT01553214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
Study NCT02752685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02752685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Study NCT04638647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab s.c. injection
Description: Secukinumab pre-filled syringes (PFS) for s.c. injection
Study NCT03948971 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venogram
Description: The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
Study NCT00445211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
Study NCT00445211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Heparin
Description: Intra-Aortic balloon Pump (IABP) without Heparin.
Study NCT02997436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle flowmetry
Description: A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded
Study NCT01426373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study NCT04219553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship
Description: The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
Study NCT03579316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adavosertib
Description: Given PO
Study NCT03579316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT03579316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03579316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO
Study NCT04295798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional tDCS
Description: The anode will be placed over F3 and the cathode over the contralateral supraorbital margin. At the beginning of stimulation, the current will be increased from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
Study NCT04295798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized tDCS
Description: This intervention will utilize eight gel electrodes with placement and current parameters optimized to the cohort, with the goal of generating an average nE over the left dlPFC of the same size as the one delivered by a conventional montage using sponges. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
Study NCT04295798 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional Sham
Description: Conventional sham will be used to maximize blinding of conventional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration described above will be used; however, current will be automatically ramped down 60 seconds after ramp-up.
Study NCT04295798 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Optimized Sham
Description: An active sham will be used in which very low-level currents (0.5 mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. We have shown that this active sham effectively blinds participants and operators to stimulation condition and does not affect functional outcomes.
Study NCT03301870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Negative Control
Description: Water for Injection, USP
Study NCT03301870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Placebo
Description: matching placebo gel
Study NCT00721578 — intervention group
Intervention type: DRUG
Intervention: voriconazole
Description: Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
Study NCT01905046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: given PO
Study NCT01905046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given PO
Study NCT02904629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL)
Description: Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT).
Study NCT02904629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Program
Description: Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
Study NCT04958993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
Description: radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
Study NCT04031664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qianjin Capsule of Gynaecology
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
Study NCT04031664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qianjin Capsule of Gynaecology
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 2 mg/kg
Description: MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICE
Description: ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICE
Description: ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHAP
Description: DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHAP
Description: DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Study NCT01453205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
Study NCT01453205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
Study NCT01453205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 4 mg/kg
Description: MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Study NCT00876850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 0796
Description: PTK 0796 100mg for injection; PTK 0796 tablet 150mg
Study NCT00876850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
Study NCT01542697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal nebulisation of magnesium sulphate
Description: intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
Study NCT01542697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intraperitoneal nebulisation of magnesium sulphate
Description: intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
Study NCT03828903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoprobe
Description: * The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding.
Study NCT01792713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertaconazole 2% cream
Study NCT01792713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00453700 — intervention group
Intervention type: PROCEDURE
Intervention: Trypanosoma cruzi serology
Study NCT00851981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TID
Study NCT00851981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SAMe
Description: 300 mg TID
Study NCT01730365 — intervention group
Intervention type: PROCEDURE
Intervention: Core biopsy procedure
Description: Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
Study NCT00924430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Study NCT00924430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Study NCT04407975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
Study NCT04407975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
Study NCT05055388 — intervention group
Intervention type: OTHER
Intervention: Multidrug-resistant bacteria
Description: Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
Study NCT01410175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional scalpel
Description: Use of conventional scalpel to incise the skin and subcutaneous layers.
Study NCT04339998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Ultrasonography (POCUS)
Description: The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole
Study NCT04103307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis cooling
Description: Cooling the blood in the CRRT circuit during delivery
Study NCT01882426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment algorithm
Description: Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
Study NCT01882426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: usual step care practice
Study NCT02839720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02839720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT01157325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial analgesia
Description: Neuraxial analgesia will be given at any time if the parturient requested analgesia
Study NCT01157325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-neuraxial analgesia
Description: No neuraxial analgesia will be given to those who will not want to an analgesia